Merck’s Welireg (Belzutifan) Receives Chinese Approval to Treat Certain Types of Von Hippel-Lindau (VHL) Disease-Related Tumors
Shots:
- The NMPA has approved Welireg for VHL disease in adults needing therapy for RCC, CNS hemangioblastomas or pancreatic neuroendocrine tumors (pNET) & not needing immediate surgery, supported by P-II (LITESPARK-004) study
- P-II study assessed Welireg (120mg, PO, QD) in subjects (n=61) with VHL disease & measurable kidney tumors not requiring surgery, until disease progression or unacceptable toxicity
- Study showed ORR of 49% (all PRs), with 56% maintaining it for ≥12mos. in VHL-related RCC (n=30/61); 63% (4% CR, 58% PR), with 73% maintaining it for ≥12mos. in VHL- related CNS hemangioblastomas (n=24) & 83% (17% CR, 67% PR), with 50% maintaining it for ≥12mos. in VHL- related pNET (n=12); mDOR not reached in any arm
Ref: Merck | Image: Merck
Related News:- Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
